We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Artificial Cells, Nanomedicine, and Biotechnology

Read the Interview with the New Editors-in-Chief

New Editors-in-Chief

RDK Misra and Wojciech Chrzanowski

The below interview offers authors interested in submitting to the journal, a guide on how to prepare their submission, plus insightful advice and updates on new policies from the journal.

Authors should carefully read the journal’s Aims and Scope and Instructions for Authors pages to ensure their manuscript adheres to the journal’s scope and editorial policies. This journal offers format-free submissions, meaning authors may submit their paper in any scholarly format or layout, but must contain all relevant sections required for peer review.


RDK Misra

Wojciech Chrzanowski

Q: Tell us about your academic and professional background and expertise. 

RDK Misra:
I am a Professor in the Department of Metallurgical and Material Engineering at The University of Texas at El Paso. My expertise is in the area of nanomedicine and bioengineering with a particular focus on biomedical diagnostics, tissue engineering, cancer therapy, drug delivery vehicles and medical devices. Other areas of interest include omics science, mechanobiology and artificial intelligence as related to biological functions.

Wojciech Chrzanowski:
I am a Deputy Director at Sydney Nano Institute and Head of Nanomedicine and Nano-Bio-Characterisation laboratory in the Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney. I am a biomedical engineer who translates the science of extracellular vesicles and bio-characterization at nanoscale to human applications. My work addresses a need for effective technologies that regulate cells to promote desired tissue repair. My laboratory pioneers the use of nanoscale characterization techniques to understand cellular communication and functionality of tissues. To this end, we develop solutions to determine the safety of nanomaterials by measuring their effects in different environments. From these we learn to design less harmful nanomaterials to keep people and the environment safe. In my laboratory, we also develop new approaches for non-invasive surgery using high intensity focused ultrasound.

Q: What kind of research is the journal most interested in covering?

Given the interdisciplinary nature of the journal, we aim to publish high quality, innovative research at the convergence of artificial cells, nanomedicine and health-related biotechnology. The journal places a strong emphasis on original research that demonstrates game changing and disruptive technologies, new concepts and innovative experimental approaches.  For work to be published, it must be of significant interest to the artificial cell, nano health and biotechnology community.

Q: Can you share the current changes recently made to the journal’s aims and scope?

The journal’s aims and scope have recently been revised, and the journal now looks to publish work that addresses unmet clinical and societal needs, such as early disease detection and effective, non-invasive therapies. The journal focuses on presenting new research across nanoscience, medicine and nano-bio-technology, including:

  • Nano and molecular systems;
  • Bioconvergance and nano-bio-info-cogno networks;
  • Smart and stimuli-responsive nanobiosystems;
  • Non-enhanced therapies and therapeutics;
  • Nanorobots and nanomachines;
  • Biosensors and wearable technologies, and
  • Artificial cells, e.g. build-a-cell

The journal puts high priority on fundamental discoveries in nanomedical sciences including origins of life, nanotoxicity, cellular communication including extracellular vesicles, and antibiotic resistance.

In addition, the journal recognizes the significance of translational science and industry-led research and offers a unique format for dissemination of the latest advances in nanofabrication, 3D printing, organ-on-chip, fusion sensors, biocharacterization and bionano- and multiscale/corelative imaging.

Q: What advice and support would you offer prospective authors putting together a submission to the journal?

The journal puts emphasis on publishing articles that have substantial scientific depth and breadth. It is essential that manuscripts fall under the scope of the journal and the author(s) present findings of major significance. I would strongly suggest that authors ask themselves a few questions before submission:

  • What is innovative in my manuscript?
  • What problem has my work addressed?
  • Who will read my paper and why?
  • What will a reader learn from my article?
  • Why are my research findings important, for whom and how do they advance science?
  • Is my study design clear and research methodology justified?

It is then necessary that articles present a cohesive ‘story’ that is supported by results, while the significance and innovation is presented in succinct discussion and conclusion sections.

It is essential that the format of the article and the presentation of the results (i.e. figures) follow the highest scientific and publishing standards, while the method section guarantees reproductivity of the experiment(s).

Q: What’s the most interesting/innovative paper you’ve seen in the journal?

The most innovative paper seen so far relates to nanomedicine, where a novel but simple method was conceived to fabricate nanoparticles of near uniform size distribution that were then modified for controlled delivery of drug at the appropriate site.

Q: How do authors benefit from publication in the journal?

Artificial Cells, Nanomedicine, and Biotechnology is a medium of disseminating research to an internationally broad audience. As an open access journal, research published by authors in the journal will be freely and permanently available so anyone, anywhere can read and build upon this research.

Furthermore, the readers discover advances that are taking place in their field, which triggers a chain reaction in terms of new ideas and thoughts to address the gaps in knowledge for possible application in the years to come. By publishing in Artificial Cells, Nanomedicine, and Biotechnology authors can reach a broad audience and influence future research.


What does the data policy 'share upon reasonable request' mean and what data is required on submission?

Data sharing is important because it allows other researchers to repeat the authors' analyses and validate their findings or to reuse the data for further analyses, thereby reducing waste. In accordance with the Taylor & Francis share upon reasonable request data sharing policy authors are required to provide a data availability statement, detailing where the data associated with the paper can be accessed. If the article includes immunostaining or microscopy images, it is mandatory to attach the full frame image with the submission. If the article includes immunoblots or PCR gels the original image should be supplied, along with molecular weight markers. It is the author's responsibility to ensure the soundness of the data, and vitally important that this detail is offered as transparently as possible.